(PharmaNewsWire.Com, August 18, 2020 ) According to the latest research report “Biofilms Treatment Market by Products (Debridement Equipment, Gauze, Dressing, Gel, Ointment), Wound Type (Traumatic, Surgical, Open, Diabetic Foot, Venous Leg Ulcer & Burns), End User (Hospital, ASCs, Wound Care Centers, Homecare)-Global Forecast to 2025”
The biofilms treatment market is projected to reach USD 2.4 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 7.9%.
Wound biofilm Market growth is driven by the rising prevalence of chronic, surgical, and traumatic wounds and the increasing incidence of burn injuries.
North America is the largest regional Wound Biofilm Market
On the basis of region, the wound biofilm market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA). In 2019, North America accounted for the largest share of the biofilms treatment market. The large share of this market can be attributed to the increasing incidence of chronic wounds, rising healthcare expenditure, the introduction of novel and specialty biofilm management products, and the presence of major market players in this region.
Key Market Players
Prominent players in the wound biofilm market include Smith & Nephew (UK), MiMedx Group Inc. (US), ConvaTec Group plc (UK), Coloplast A/S (Denmark), Mölnlycke Healthcare AB (Sweden), Organogenesis Holdings Inc. (US), Integra LifeSciences Holdings Corporation (US), B. Braun Melsungen AG (Germany), PAUL HARTMANN AG (Germany), Medline Industries Inc. (US), Acelity (US), Misonix (US), Zimmer Biomet Holdings Inc. (US), Kerecis (Iceland), Welcare Industries S.p.A (Italy), Medaxis AG (Switzerland), PulseCare Medical (US), Arobella Medical, LLC (UK), RLS Global AB (Sweden), Mil Laboratories Pvt. Ltd. (India).
Smith and Nephew (UK) is the leading player in the global biofilms treatment market. The company focuses on product launches and acquisitions to increase its share in the biofilms treatment market. Smith and Nephew is a pioneer in advanced wound care and has been in the market for more than 15 years, which provides it with a competitive edge. Also, the company is focusing on increasing its customer base and expanding its reach in untapped emerging markets.
In May 2020, ConvaTec announced the launch of ConvaMax, which helps in managing highly exuding wounds, including leg ulcers, surgical wounds, and diabetic foot ulcers. In September 2018, ConvaTec Group received US FDA 510(k) clearance for its AQUACEL Ag Advantage antimicrobial dressings. In 2017, Smith and Nephew launched MolecuLight i: X, a handheld wound imaging device, in Europe. This device instantly measures wound surface area and shows the presence and distribution of potentially harmful bacteria.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
